Literature DB >> 20010022

Differentiating generalized anxiety disorder from anxiety disorder not otherwise specified.

Amy E Lawrence1, Timothy A Brown.   

Abstract

The diagnostic criteria for generalized anxiety disorder (GAD) have elicited numerous criticisms and suggestions for revision. Several researchers have noted that many patients fail to meet full criteria for the disorder, but nevertheless experience clinically significant symptoms. These "subsyndromal" cases are labeled anxiety disorder not otherwise specified (AnxNOS) under the current diagnostic system. The purpose of the this study was to determine the diagnostic criteria most often "missed" in cases that resemble GAD, but do not meet full criteria for the diagnosis. Individuals diagnosed with AnxNOS (n = 146) were compared with those diagnosed with GAD (n = 146) and other anxiety disorders (n = 146) on self-report measures, clinician ratings, and rates of comorbidity. Although individuals with AnxNOS reported clinically significant symptoms, they reported less worry, negative affect, depression, and comorbidity than individuals diagnosed with GAD. Findings are discussed with regard to their implications for revisions to the diagnostic criteria for GAD.

Entities:  

Mesh:

Year:  2009        PMID: 20010022     DOI: 10.1097/NMD.0b013e3181c29992

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  6 in total

1.  Specifying child anxiety disorders not otherwise specified in the DSM-IV.

Authors:  Jonathan S Comer; Kaitlin P Gallo; Priya Korathu-Larson; Donna B Pincus; Timothy A Brown
Journal:  Depress Anxiety       Date:  2012-07-16       Impact factor: 6.505

2.  The Contribution of Worry Behaviors to the Diagnosis of Generalized Anxiety Disorder.

Authors:  Timothy A Brown; Esther S Tung
Journal:  J Psychopathol Behav Assess       Date:  2018-05-10

3.  Threshold and subthreshold generalized anxiety disorder among US adolescents: prevalence, sociodemographic, and clinical characteristics.

Authors:  M Burstein; K Beesdo-Baum; J-P He; K R Merikangas
Journal:  Psychol Med       Date:  2014-01-02       Impact factor: 7.723

Review 4.  Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials.

Authors:  Siegfried Kasper; Markus Gastpar; Walter E Müller; Hans-Peter Volz; Hans-Jürgen Möller; Angelika Dienel; Sandra Schläfke
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 5.  A proposal for a dimensional classification system based on the shared features of the DSM-IV anxiety and mood disorders: implications for assessment and treatment.

Authors:  Timothy A Brown; David H Barlow
Journal:  Psychol Assess       Date:  2009-09

6.  Characteristics of subjects with comorbidity of symptoms of generalized anxiety and major depressive disorders and the corresponding threshold and subthreshold conditions in an Arab general population sample.

Authors:  Jude U Ohaeri; Abdel W Awadalla
Journal:  Med Sci Monit       Date:  2012-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.